Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 8, 2026 | Solaris Endovascular Reports Exceptional 6-Month Results with Solaris DE at CIRSE 2026 | Sirolimus eluting from covered stent platform Complete DEScover dataset demonstrates 92.7% overall TLPP and 79.9% overall ACPP at six months, with primary safety endpoint met The complete 6-month results strengthen our conviction that Solar... |
| Sep 1, 2026 | Complete 6-Month DEScover Results for Solaris DE to be Presented at CIRSE 2026 | sirolimus eluting covered stent Solaris Endovascular Complete dataset follows encouraging interim results demonstrating 95% TLPP and 82% ACPP with investigational Solaris DE The complete 6-month dataset will provide a more comprehensive ass... |
| Jul 7, 2026 | Solaris Endovascular Strengthens Leadership Team with Appointment of Rowan Hettel as CTO and David Stack as Director | Rowan and David bring proven records of developing medical technologies, building companies, and creating shareholder value.” — Randy HubbellDALLAS, TX, UNITED STATES, July 7, 2026 /EINPresswire.com/ -- Solaris Endovascular, Inc., a medical... |
| May 5, 2026 | Solaris Endovascular Receives FDA Breakthrough Device Designation for Solaris DE™, a new Drug-Eluting Covered Stent | Sirolimus eluting from covered stent platform We are grateful for this Breakthrough Device Designation from the FDA, recognizing that the patients we serve cannot afford to wait.” — Dr. Marco CostaDALLAS, TX, UNITED STATES, May 5, 2026 /EIN... |
| Jan 8, 2026 | Solaris Endovascular Announces Completion of Enrollment in DEScover Trial | Sirolimus eluting from covered stent platform Enrollment milestone achieved ahead of schedule as Solaris DE drug-eluting continues to gather additional clinical evidence of safety and performance. Completing DEScover enrollment ahead of sch... |
| Oct 27, 2025 | Solaris Endovascular Reports Positive Six-Month Interim Results for DEScover Trial | Solaris DE Logo First Drug-Eluting Self-Expanding Covered Stent Demonstrates 95% Patency Through 6 Months; 100% Procedural Success and Zero 30-Day Device Related Adverse Events We believe these results position Solaris DE to become the new ... |
| Sep 2, 2025 | Solaris Endovascular Exceeds Enrollment Milestone for DEScover Trial; Interim Data to be Shared at Vascular Conferences | Solaris DE Logo 80% of Patients Now Enrolled in Pioneering Drug-Eluting Covered Stent Graft Study We are very pleased with the pace of enrollment in the DEScover trial and look forward to sharing interim data at upcoming conferences this fa... |
| Feb 18, 2025 | Solaris Endovascular, Inc. Surpasses Key Enrollment Milestone in DEScover Randomized Clinical Trial | Solaris Endovascular Inc 42 Patients Enrolled in Pioneering Drug-Eluting Covered Stent Graft Study NEW ORLEANS, LA, UNITED STATES, February 19, 2025 /EINPresswire.com/ -- Solaris Endovascular, Inc., a leading US-based medical device company... |
Reviews 0
FAQ about Solaris Endovascular
What has the press written about Solaris Endovascular?
Parsers VC has collected 9 articles mentioning Solaris Endovascular, among them “Solaris Endovascular Reports Exceptional 6-Month Results with Solaris DE at CIRSE 2026” (Sep 8, 2026) and “Complete 6-Month DEScover Results for Solaris DE to be Presented at CIRSE 2026” (Sep 1, 2026).
Is Solaris Endovascular still active?
Solaris Endovascular is probably closed: its latest activity on Parsers VC dates from Sep 29, 2026.